ADMA Biologics (NASDAQ:ADMA) Sets New 52-Week High After Analyst Upgrade

ADMA Biologics, Inc. (NASDAQ:ADMA)’s share price hit a new 52-week high during mid-day trading on Friday after HC Wainwright raised their price target on the stock from $18.00 to $26.00. HC Wainwright currently has a buy rating on the stock. ADMA Biologics traded as high as $22.30 and last traded at $21.67, with a volume of 779556 shares. The stock had previously closed at $19.72.

ADMA has been the topic of a number of other research reports. Raymond James lifted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $21.25.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Quest Partners LLC bought a new position in shares of ADMA Biologics in the second quarter valued at about $29,000. Hollencrest Capital Management acquired a new stake in ADMA Biologics in the third quarter worth about $30,000. EntryPoint Capital LLC acquired a new stake in ADMA Biologics in the first quarter worth about $31,000. CWM LLC increased its position in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in ADMA Biologics in the second quarter worth about $93,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Stock Performance

The stock has a 50-day moving average of $18.12 and a 200 day moving average of $13.89. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. The stock has a market capitalization of $5.27 billion, a price-to-earnings ratio of 161.57 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company’s revenue was up 78.4% on a year-over-year basis. During the same period last year, the company earned ($0.02) earnings per share. On average, analysts expect that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.